Protecting Canadians from excessive drug prices: H82-28/2017E-PDF
consulting on proposed amendements to the Patented Medicines Regulations.
"In January 2016, federal, provincial and territorial Ministers agreed to work together to improve the affordability, accessibility and appropriate use of prescription drugs to better meet health care system needs. ... This important work includes reducing the cost of patented drugs through the modernization of the pricing framework under the Patented Medicine Prices Review Board (PMRPB). Under the authority of the Patent Act and through the Patented Medicines Regulations (“Regulations”), the Government of Canada regulates the prices of patented medicines in Canada to ensure that prices are not excessive. Despite significant changes in the pharmaceutical market, the regulations have not been substantively changed in over two decades. Health Canada is consulting stakeholders and interested members of the public on proposed amendments to the Regulations, to equip the PMPRB with more relevant and effective regulatory tools to better protect Canadians from excessive prices for patented drugs. ... Feedback received on or before June 28th, 2017, will be considered in developing a regulatory proposal under the Patent Act to protect Canadians from excessive drug prices. A summary of comments will be published in the RIAS statement at Canada Gazette, Part I"--p. 3 and p. 16.
|Collaborating Author||Patented Medicine Prices Review Board.|
|Title||Protecting Canadians from excessive drug prices|
|Subtitle||consulting on proposed amendements to the Patented Medicines Regulations.|
|Other Language Editions||[French]|
|Electronic Document|| |
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact the authoring department to request a format other than those available.
We invite you to consult the Frequently Asked Questions page for additional information regarding the Archived Content notice.
Note: The URLs contained in this/these document(s) may no longer be functional
|Note||Cover title. "This consultation period is 6 weeks, running from May 16, 2017 to June 28, 2017"--p. 5. Issued also in French under title: Protéger les Canadiens des prix excessifs des médicaments : consultation sur les modificaations proposées au Règlement sur les médicaments brevetés.|
|Number of Pages||16 p. :|
|Subject Terms||Drugs, Price regulation, Reform, Consultations|
- Date modified: